Most somatic human cells lack telomerase activity because they do not express the telomerase reverse transcriptase (hTERT) gene. Conversely, most cancer cells express hTERT and are telomerase positive. For most tumors it is not clear whether hTERT expression is due to their origin from telomerase positive stem cells or to reactivation of the gene during tumorigenesis. Telomerase negative cells lack detectable cytoplasmic and nuclear hTERT transcripts; in telomerase positive cells 0.2 to 6 mRNA molecules/cell can be detected. This suggests that expression is regulated by changes in the rate of hTERT gene transcription. In tumor cell lines hTERT expression behaves like a recessive trait, indicating that lack of expression in normal cells is due to one or several repressors. Studies with monochromosomal hybrids indicate that several chromosomes may code for such repressors. A number of transcription factors, tumor suppressors, cell cycle inhibitors, cell fate determining molecules, hormone receptors and viral proteins have been implicated in the control of hTERT expression; but these studies have not yet provided a clear explanation for the tumor speci®c expression of the hTERT gene, and the cis-acting elements which are the targets of repression in normal cells still have to be identi®ed.
Introduction
Telomerase is the enzyme required for the addition of telomeric repeats to the ends of linear chromosomes. It consists of a reverse transcriptase, TERT, that carries its own template in the form of an RNA moiety, TER. In vitro this complex can add telomeric repeats to arti®cial substrates. Its activity in vivo depends on other components some of which probably control the access of the enzyme to chromatid ends (Evans and Lundblad, 2000) . In the absence of telomerase the telomeres of normal cells shorten by about 50 nt per cell population doubling (Counter et al., 1992; Harley et al., 1990; Human et al., 2000) . In adult humans the enzyme is present in the germ line stem cells that give rise to mature gametes as well as in at least certain stem cell populations and in activated lymphocytes, but not in dierentiated cells (Chiu et al., 1996; . In the absence of telomerase activity human somatic epithelial cells and ®broblasts can undergo approximately 50 to 60 population doublings before telomere shortening leads to replicative senescence (see e.g. Bodnar et al., 1998) . In rodents TERT expression is maintained during dierentiation, and cellular senescence is not due to absence of telomerase (Russo et al., 1998) . Observations on TER-de®cient mice indicate that the enzyme is not required for the development and normal life span of laboratory mice in early generations (Blasco et al., 1997) . However, propagation of mTER7/7 mice for three or more generations leads to extensive telomere shortening and aects development and function of multiple tissues (Lee et al., 1998) . In several human cell types ectopic expression of human TERT (hTERT) is sucient to induce in vitro and in vivo telomerase activity and to`immortalize' the cells, indicating that none of the other components is limiting (Bodnar et al., 1998; Morales et al., 1999; Vaziri and Benchimol, 1998; Yang et al., 1999a) .
There is a striking correlation between the presence of hTERT mRNA and telomerase activity (see e.g. Ducrest et al., 2001) , and this has been taken to suggest that hTERT expression is regulated through changes in the rate of transcription, but direct evidence for this is scarce. Post-transcriptional regulation of hTERT expression through alternative splicing has been observed during human development (Ulaner et al., 2001) , and there have been claims that posttranslational modi®cations can aect TERT activity (Kang et al., 1999; Kharbanda et al., 2000; Liu et al., 2001; Yu et al., 2001) , but the role of such mechanisms in tumor speci®c telomerase expression is, as yet, quite unclear. The ®nding that most tumors express hTERT and telomerase activity (Kim et al., 1994) , and that in vitro transformation of telomerase negative human cells requires activation of hTERT expression (Hahn et al., 1999) indicates that maintenance of telomeres is required for the unlimited proliferative potential of tumor cells. This conclusion is supported by the ®nding that telomerase negative in vitro transformed cells maintain telomeres through an alternative (ALT) pathway that is based on somatic recombination (Bryan et al., 1995; Dunham et al., 2000) .
For oncology the importance of understanding the mechanisms that control hTERT expression in tumors is twofold; on the one hand, it may lead to the discovery of targets for new cancer therapies, and on the other hand it might provide cis-acting regulatory elements that could contribute to tumor targeting of tumoricidal genes or viruses. Thus, it is not surprising that there have been a large number of groups that have tried to dissect the mechanisms that control hTERT expression. In this review we discuss this work, limiting ourselves to eorts to elucidate the mechanisms regulating hTERT mRNA levels, and try to explain why so far it has provided few if any conclusive answers that would be helpful to oncologists.
Maintenance of expression or activation of the hTERT gene?
Human skin or lung ®broblasts do not express hTERT, and senesce after 50 to 60 population doublings. Ectopic expression of hTERT renders these as well as endothelial cells`immortal' without inducing any changes in their karyotype or other signs of transformation (Bodnar et al., 1998; Jiang et al., 1999; Morales et al., 1999; Vaziri et al., 1999; Yang et al., 1999a) . There is no report of spontaneous immortalization of normal ®broblasts, but SV40 infection, by blocking the p53 and p16 dependent pathways that arrest cells when they reach senescence, extends their life span (see Duncan and Reddel, 1997 for review). These cells eventually hit a`crisis' during which almost all cells die with the exception of a few transformed survivors that either maintain their telomeres by the ALT pathway (see Reddel et al., 1997 for review) or express hTERT. In this case there is no doubt that hTERT expression has been reactivated. Whether this occurs in tumors is much less clear (for a discussion of this issue see Greaves, 1996; Shay and Wright, 1996) . There is evidence that some, perhaps most, tumors are derived from cells that have already gained their ®rst alterations towards malignant transformation before undergoing dierentiation, close to a stem-cell like stage when hTERT may still have been expressed. The clearest case can probably be made for colorectal carcinoma. Colorectal adenomas are derived from crypt cells some of which can express hTERT, as detected by in situ hybridization (Kolquist et al., 1998) . Many adenomas themselves contain hTERT expressing cells but a proportion of them lack detectable telomerase activity (Yan et al., 2001) . This may re¯ect the fact that most adenoma cells undergo dierentiation and eventually die, while a small variable number of undierentiated cells ensure the survival of the tumor. These may be the hTERT positive cells detected in situ.
Thus, in most carcinomas hTERT expression may not be due to reactivation of the hTERT gene but to the fact that the cells which maintain the tumor are prevented from dierentiating and maintained in a stage at which their normal counterparts still express hTERT. The ®nding that the frequency of telomerase negative sarcomas is higher than that of carcinomas suggests that sarcomas might be more frequently derived from hTERT negative cells for which there is no preferential choice of the mechanism through which they stabilize chromosome ends (Carroll et al., 1999) .
Why do tumor cells need telomerase?
Telomeres are structures that prevent the ends of a linear chromosome to be mistaken for a double strand break (Godhino Ferreira and Promisel Cooper, 2001; McClintock, 1941; van Steensel et al., 1998) . If these structures are disrupted, the cell attempts to repair the break and, in doing so, generates fusions between the telomeres of dierent chromatids. Fusions occur when the number of telomeric repeats drops below a critical level, in cells which lack telomerase (Blasco et al., 1997; Hackett et al., 2001) and do not express an ALT pathway. Thus, most tumor cells need telomerase to maintain telomeres suciently long to keep the incidence of chromosome fusions low. However, telomere attrition to a level at which telomeres cease to protect chromosome ends requires 50 to 60 cell doublings, and it is not clear whether the cells in a tumor have indeed undergone that many divisions, even taking into account cell loss due to dierentiation and death. It seems important to consider alternative reasons for the hTERT expression by most tumors. One explanation may lie in the chromosomal instability that characterizes most cancer cells (Parshad and Sanford, 2001; see Sen, 2000 for review) . At least some of this instability arises from the breakage and fusion of chromosomes. Indeed, breakage is involved in the ampli®cation of oncogenes or genes conferring drug resistance, through breakage-fusion-bridge cycles (Coquelle et al., 1997 (Coquelle et al., , 1998 . Although chromosome breaks can provide the cellular substrate for the selection of more aggressive tumor cells, they will also give rise to non-viable cells. One way to keep these processes in check is through de novo addition, by telomerase, of telomeres to the ends of broken chromosomes (Friebe et al., 2001; Hande et al., 1998; Varley et al., 2000) . This would mean that premalignant cells, which express hTERT, have an advantage over the others not only when cells have undergone more than 50 to 60 divisions, but at a much earlier stage when chromosome breakage becomes frequent.
Is hTERT expression regulated by changes in the level of gene transcription?
As pointed out above there is a very strong correlation between telomerase expression and the presence of detectable hTERT mRNA (Meyerson et al., 1997; Nakamura et al., 1997) . We have compared the numbers of hTERT molecules per cell, determined by quantitative RT ± PCR, in a number of cell lines from dierent tissue origins (Ducrest et al., 2001) . In all telomerase positive cells hTERT transcripts are detectable but rare (0.2 to 6/cell) whereas no transcripts (50.004/cell) could be detected in telomerase negative cells. This correlation has been widely assumed to re¯ect regulation of hTERT expression via control of the rate of transcription. But it is equally compatible with regulation of transcript processing or changes in the mRNA half-life. Although a considerable number of transcription factors have been implicated in the control of hTERT expression, direct evidence that hTERT gene transcription is regulated is scarce. Speci®cally it is unclear whether the tumor speci®c expression of hTERT is controlled at the level of transcription. The ®nding that activation of a c-Mycestrogen receptor ligand binding domain fusion can increase hTERT mRNA levels in the absence of protein synthesis shows that ectopic c-Myc can indeed directly stimulate transcription of the gene (Greenberg et al., 1999; Oh et al., 2000; Wu et al., 1999) . We will discuss the biological role of c-Myc in hTERT regulation below.
Run-on nuclear experiments which measure the average loading of RNA-polymerase molecules on the gene, have been reported for one leukemia cell line (U937) (Gunes et al., 2000) . This study indicated that in these cells hTERT is regulated at the level of transcription rather than RNA stability. We have made attempts to obtain similar evidence for a tumor cell line derived from ®brosarcoma (HT1080) that contains relatively high numbers of hTERT transcripts among the cell lines screened by us, and have been unable to detect run-on transcription signals above background. The probable reason for this failure is that the rate of transcription is too low in HT1080 cells to be detectable by this approach. Comparing the levels of spliced cytoplasmic mRNA with that of intron-containing nuclear transcripts in dierent telomerase positive and negative cell lines, we observed that telomerase negative cells did not contain detectable levels (50.004 molecules/cell) of either cytoplasmic mRNA or nuclear transcripts, whereas telomerase positive cells contained both transcript forms (Ducrest et al., 2001) . These results clearly suggest that hTERT mRNA levels are indeed controlled at the level of gene transcription, but they do not exclude that regulation involves changes in the eciency of nuclear processing of primary transcripts.
Possible models of hTERT regulation
In a sense hTERT behaves like a protooncogene; abnormal maintenance or reactivation of expression contributes to tumorigenesis. Thus, one would expect that genomic changes that can lead to improper expression of protooncogenes, such as translocations that include the regulatory regions, would also be found in the hTERT genes of tumors.
Indeed, there is one study suggesting that the integration of the hepatitis B viral genome into the 5' flanking region of the hTERT gene might induce its expression in a hepatocellular carcinoma. We have found no evidence for rearrangements in the 5' flanking region and the 5' half of the gene (710 to +25 kb) screening a number of cell lines of divers origin. The second intron of the hTERT gene contains a meiotically unstable minisatellite with several putative binding sites for c-Myc (Szutorisz et al., 2001; Wu et al., 1999) . Size rearrangements of that minisatellite are not required for telomerase expression in colon carcinomas (Szutorisz et al., 2001) . In 31 of 33 colon carcinomas that were heterozygous for the polymorphic minisatellite the 1 : 1 ratio of hTERT alleles was maintained, indicating that there had been no gene ampli®cation in these tumors. In the two remaining tumors there was a change compared to normal tissue from the same patient, compatible with ampli®cation of one hTERT allele. Ampli®cation of the hTERT gene was also detected in another study, in 20% of primary tumors and 40% human cancer derived cell lines (Zhang et al., 2000) . Ampli®cation may be the result of selection for higher expression of an active hTERT gene. It might also lead to the expression of an inactive gene as a consequence of the genomic rearrangements that give rise to ampli®cation, or through titration of a gene speci®c repressor.
Another modi®cation that might aect hTERT expression is DNA methylation. Turning o the expression of tumor suppressor genes or genes involved in DNA repair, through methylation of their promoter, can contribute to carcinogenesis. Comparison of the methylation status of the hTERT promoter in telomerase positive and negative cells has not provided any compelling clues that this type of modi®cation controls tumor speci®c hTERT expression (Dessain et al., 2000; Devereux et al., 1999) .
hTERT expression due to cis-acting gene rearrangements should behave like a dominant trait. Dominant expression would also be likely if demethylation of the hTERT promoter were the mechanism through which hTERT expression is activated in tumors. However, so far no cross in which hTERT expression is dominant has been reported. On the other hand there is a number of tumor lines in which hTERT expression behaves like a recessive trait; expression is extinguished in hybrids with telomerase negative cells or by transfer of a single chromosome from a normal cell (Table 1 ) (Bryan et al., 1995; Cuthbert et al., 1999; Nishimoto et al., 2001) . This suggests that hTERT expression in normal cells is repressed by a mechanism which is no longer functional in tumors. The simplest model that accounts for these observations is that hTERT transcription is under the control of a repressor, absent in cancer cells, that acts via a cisacting element in the hTERT gene. Note, that the repressor may not itself be a sequence speci®c DNAbinding protein, but could be a co-repressor interacting with a transcription factor. The data are equally compatible with a model according to which the approach is most advanced is chromosome 3. Upon introduction of a normal chromosome 3, two renal, one breast, and one cervical carcinoma line ceased to express hTERT. Two groups using either a kidney renal carcinoma (Tanaka et al., 1998) or a breast cancer derived line (Cuthbert et al., 1999) as recipients have narrowed the region that confers repression to p14.2 ± 21.1. This region overlaps with a segment of chromosome 3 that undergoes frequent LOH in breast cancer (Maitra et al., 2001) . LOH and deletions of smaller parts of 3p have been identi®ed in breast, cervix, colon, lung, and renal carcinomas (Kok et al., 1997) . In a single study both chromosome 3 and 4 have been found to shut o hTERT expression in HeLa cells. This suggests multiple independent pathways of repression. Since mutations aecting a repressive pathway are recessive, activation of hTERT expression through such mutations would be expected to be an extremely rare event. It might explain why spontaneous immortalization of normal ®broblasts has never been observed.
Other approaches to study regulation of hTERT expression
Screening candidate molecules
The mapping and cloning of genes on normal chromosomes that shut o hTERT expression in tumor cells is one approach towards the elucidation of the regulation of hTERT expression. Other, complementary approaches consist in (1) the testing of candidate molecules for their eect on the expression of the endogenous hTERT gene, or (2) attempts to identify the cis-acting elements in the hTERT gene that control its expression. The former approach is based on guesses as to what molecules might be involved in hTERT regulation which can be tested either through the ectopic expression of such putative positive regulators in hTERT negative cells, or through the expression of dominant negative version of such molecules in hTERT expressing cells. The latter is a better approach that can provide informative data even if the results are negative. Candidates include molecules whose abnormal expression in tumor cells prevents their dierentiation, such as c-Myc, TCF or Notch. The second approach aims at the identi®cation of cis-acting regulatory sequences in or near the hTERT gene through experiments using reporter gene constructs and including in vitro assays for DNA binding proteins, nuclease hypersensitivity, in vivo footprinting assays and ChromatinIP.
Numerous molecules, including transcription factors, regulators of dierentiation and the cell cycle, and proteins of viruses implicated in tumorigenesis, have been proposed to regulate hTERT expression. We have attempted to summarize the most relevant ®ndings in Table 2 and Figure 1 , without being exhaustive in our literature citations. Many studies were based on the This eect does not depend on protein synthesis and is therefore likely to be due to a direct action of c-Myc protein on the hTERT gene (Greenberg et al., 1999; Oh et al., 2000; Wu et al., 1999) . Mad, the antagonist of c-Myc was shown to be a potential repressor of hTERT. Mad was a candidate repressor identi®ed in a gene screen for hTERT regulators (Oh et al., 2000) and a rise in endogenous Mad RNA and protein levels was inversely correlated with hTERT RNA levels (Gunes et al., 2000; Oh et al., 2000; Xu et al., 2001) . Finally, while c-Myc protein was found associated with the hTERT gene in vivo in telomerase-positive promyelocytic leukemia HL60 cells as determined in chromatin immunoprecipitation assays (Xu et al., 2001) (Grandori et al., 2000; Obaya et al., 1999) , but there is no evidence that this change is sucient to induce hTERT expression. (3) Overexpression of HPV16 E7, which is important for immortalization of keratinocytes, induces high level of c-Myc protein but is unable to activate telomerase expression (Gewin and Galloway, 2001; Veldman et al., 2001) . (4) In the breast cancer derived cell line 21NT chromosome 3 transfer leads to immediate repression of the hTERT gene but expression of c-Myc, Mad1 and cMyc target genes remained unchanged (Ducrest et al., 2001) . Therefore, the putative repressor on chromosome 3 does not regulate hTERT through c-Myc or one of its coregulators. In conclusion, it seems likely that normal changes in the c-Myc/Mad ratio control hTERT transcription in cells in which the gene is not closed' by one or several repressors, but that the levels of c-Myc in most tumors are not high enough to overcome repression. One obvious possibility is that in normal cells competent to express the gene c-Myc links hTERT expression to the proliferative status of the cell. Other genes involved in the control of cell cycle progression have been suggested to repress hTERT expression such as p53, p16, p21, and E2F-1 (Table 2 and Figure 1) . However, the eect of these genes on hTERT expression remains ambiguous. The best case can be made for p53, which was shown to downregulate hTERT expression. This eect seems to be independent of p53 induced cell cycle arrest and apoptosis Kusumoto et al., 1999; Xu et al., 2000) . Another case in which hTERT can be regulated independently of dierentiation and/ or growth inhibition is the acute promyelocytic leukemia cell line NB4-R1, in which treatment with retinoic acid dowregulates hTERT without inducing maturation (Pendino et al., 2001 ).
As suggested above hTERT expression in most carcinomas may not be due to a reactivation of the hTERT gene but re¯ect the advantage, during tumor progression of cells in which dierentiation is partially or completely blocked and, as a consequence, hTERT expression maintained. This view would predict that pathways which control cell dierentiation and which are frequently deregulated in cancer, such as the Notch and the Wnt pathways may be implicated in hTERT regulation. We have found that in the breast cancer cell line, 21NT, overexpression of the intracellular part of the Notch 1 protein increases the expression levels of hTERT transcripts as well as of HES-1, a known Notch 1 target (A Ducrest; unpublished data). Similarly, arguing that TCF activity may be required for hTERT expression in colon carcinoma cells we have determined the levels of hTERT mRNA in four colon carcinoma cell lines carrying tetracycline inducible constructs coding for dominant negative version of TCF1 or TCF4. These lines were prepared by Marc van de Wetering in the laboratory of Hans Clevers. Tetracycline treatment of such cells leads to a signi®cant down-regulation of a number of TCF target genes expressed in colon carcinomas, but had no eect on hTERT transcript levels which were comparable to that in control cells from the same tumors lacking the dominant negative TCF constructs. These results quite strongly argue that TCF does not play a role, direct or indirect, in controlling hTERT expression in colon carcinomas.
In estrogen-targeted tissues, such as endometrium (Kyo et al., 1997; Saito et al., 1997; Takakura et al., 1999) , prostate (Meeker et al., 1996) and epithelial cells with high renewal potential (Bednarek et al., 1998) estrogen-responsive cells may be more prone to form tumors (Hilakivi-Clarke, 2000; Liehr, 2000) because they are telomerase positive. Estrogen was shown to activate hTERT promoter constructs through estrogen responsive elements (ERE) in the hTERT 5' flanking region. This activation was dependent on the presence of estrogen receptor-a. Genomic footprinting indicated that one ERE element, 950 bp upstream of the translation start site, is occupied in vivo in cells expressing, but not in cells lacking, the estrogenreceptor-a (Misiti et al., 2000) . This is in agreement with the ®nding that tamoxifen, an antagonist of estrogen, reduces telomerase activity in the breast cancer cell line MCF-7 cells (Aldous et al., 1999) . Positions of chromatin IP (ChIP) or in vivo footprint (iv).
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Since in this line estrogen also increases c-Myc levels , c-Myc may contribute to activation of hTERT transcription.
On the use of hTERT-reporter constructs
There have been many attempts to identify cis-acting regulatory elements in the hTERT gene through the use of reporter constructs (see Table 2 and Figure 1 ). The main a priori limitation of this approach is that it makes assumptions on the location of the regulatory elements, which can be at considerable distance, 3' or 5' of the gene, or in introns. Furthermore, certain regulatory elements might not work outside of their endogenous context. Therefore the use of the basic reporter construct should be validated in experiments testing whether it contains the cis-acting elements controlling the expression of the endogenous gene, e.g. by transfection into appropriate cell lines. Claims that hTERT reporter expression re¯ects that of the endogenous gene have been based on the comparison of reporter expression in normal cells with that in various cell lines. However, in vitro transformed or tumor cells dier from normal cells in many respects that can aect the rate of gene transcription in ways which are unrelated to gene speci®c regulation. To solve this problem we (Ducrest et al., 2001 ) have compared the expression of a series of reporter constructs containing the hTERT promoter and up to 7.5 kb of 5' flanking region in two SV40 transformed ®broblast lines. One of these is telomerase positive, whereas the other uses the ALT pathway and contains no detectable hTERT transcripts. All reporter constructs were more strongly expressed in either line than in normal ®broblasts, and there were no signi®cant dierences between the activity of any of the reporters in the telomerase positive and the ALT line. Knight et al. (2001) have also reported hTERT promoter activity in an ALT cell line SUSM-1 when using another reporter containing 1.7 kb of the hTERT¯anking region. Even more strikingly, we observed no dierences in the expression of the same hTERT reporters when we compared them in a breast carcinoma line and its derivatives in which transfer of a single normal chromosome 3 has reduced hTERT mRNA by at least 30-fold, to undetectable levels (Ducrest et al., 2001) . Thus, by these stringent criteria the validation of hTERT reporters containing the longest 5' flanking segment tested so far has completely failed, and the signi®cance of the results obtained with similar constructs in other cells (see Table 2 ) has to be assessed in the light of this failure. Of course, this does not mean that regulatory sites identi®ed in constructs expression which does not mimic that of the endogenous gene have no role in the regulation of the latter, but without strong additional evidence such identi®cations provide only very weak arguments. The ®nding that an element identi®ed in this way indeed binds a transcription factor that might be implicated in the regulation in vitro adds very little weight to the argument. Strong evidence that binding of a transcription factor to a putative regulatory site plays a role in the control of gene expression requires demonstration that the factor occupies the site in vivo, most convincingly by ChromatinIP with antibodies against the putative regulator. But even such experiments cannot, by themselves, prove that the transcription factor in question controls the dierence in hTERT gene expression in normal versus tumor cells. It is quite possible that certain transcription factor binding sites are indeed occupied in hTERT expressing but not in telomerase negative cells, and that occupation is required for hTERT transcription. But occupancy may re¯ect that fact that in cells competent to express the gene these sites are`open' i.e. accessible to the transcription factor, due to chromatin alterations that depend on other proteins which bind elsewhere and are higher up in the hierarchy of control.
Screening for changes in hTERT chromatin
The search for dierences between the conformation of the chromatin containing the hTERT gene in hTERT expressing and non-expressing cells provides a complementary approach to the identi®cation of cis-acting elements. The classical method used is to screen the locus of interest for sites with dierential sensitivity to nucleases such as DNaseI or Micrococcal nuclease (MNase). In numerous instances the activity of a regulatory element correlates with the presence of a nuclease hypersensitive site or region at or near the element. Compared to ChromatinIP, this type of analysis has the advantage that it can be applied to very large genomic segments without previous assumption about the possible localization of regulatory elements, but it has the disadvantage that there are no strict rules describing the relationship between, say, transcription factor occupancy of a regulatory site and its nuclease sensitivity. Thus, lack of nuclease sensitive sites in a segment does not exclude that it plays a regulatory role. Application of the technique to the hTERT gene has to face another uncertainty; as discussed above the rate of hTERT gene transcription is probably very low (Ducrest et al., 2001) , and even in a cloned hTERT positive cell line not all cells may transcribe the gene at a given moment. This may ± or may not ± mean that important regulatory elements in the gene are not always occupied, and that the corresponding nuclease hypersensitive sites are invisible in the background of chromatin from nontranscribed genes. Nevertheless, comparison of dierent telomerase positive and negative cell lines points to the existence of two nuclease sensitive sites in the second intron of telomerase expressing cells, and the signi®cance of these sites has been validated by the stringent type of criteria outlined above for reporter construct analysis (H Szutorisz, manuscript in preparation). It remains to be seen whether these sites are the primary targets of the molecules that induce hTERT transcription in tumors, or whether these chromatin alterations are the downstream consequence of the activity of cis-acting elements elsewhere in the gene.
Outlook
One impression that emerges from this review is that in spite of considerable eorts by many groups, our understanding of the mechanisms that are responsible for the tumor speci®c expression of the human TERT gene is still very poor. This raises two questions. On the one hand one has to ask what new or at least modi®ed approaches are most likely to be more successful than the attempts carried out so far, and on the other one is lead to consider the possibility that the models which determine the choice of methods are inappropriate or wrong.
At this time it seems that the approach which is most likely to provide insight into the regulation of hTERT expression is the positional cloning of genes on chromosomes that shut o hTERT expression upon microcell mediated transfer into tumor cell lines. However, it is by no means certain that such genes once they have been identi®ed provide immediate clues as to the mechanisms through which they aect hTERT expression, and to unravel these mechanisms it would certainly be extremely useful if not essential to have a reporter system which does mimic the expression pattern of the endogenous hTERT gene according to the stringent criteria outlined above. To build such a system may require the use of much larger genomic segments as they are available, e.g., in BAC clones. BAC clones containing the hTERT gene are available but their sequence is not yet publicly accessible. Reporter constructs based on BAC clones of other genes have been successfully used for the study of regulation, but the technical investment required is not trivial, and one needs to take into account the risk that the experiments fail because of the very low level of hTERT transcription.
If a reporter system that faithfully reproduces the tumor-speci®c regulation of the hTERT gene were available, it might be informative to determine its expression pattern in transgenic mice. As pointed out earlier, the TERT of the mouse (mTERT) and other rodents is not shut o in dierentiated somatic cells (Russo et al., 1998) . This dierence between rodents and man may re¯ect changes in the cis-acting elements or in the expression of transacting factors. If hTERT gene expression in the mouse resembles that in man this would argue strongly that repression of hTERT expression during dierentiation is due to dierences in cis-acting elements only. What evolutionary pressure may have led to the somatic repression of hTERT expression? A simple idea is that this may be related to the species' life-span; in species that reach reproductive age late, repression of telomerase activity which provides an important barrier to malignant disease should confer a stronger selective advantage than in species with a short life-span. Not enough species have been analysed to allow evaluation of this hypothesis.
There are several aspects of hTERT expression that are puzzling and apparently contradictory. The ®nding that immortalization of normal ®broblasts by spontaneous activation of hTERT expression has never been observed, and that it is a rare event even after viral transformation, is hard to reconcile with the ®nding that it is quite easy to turn on hTERT expression in normal cells, through overexpression of c-Myc or treatment with an inhibitor of histone deacetylases Takakura et al., 2001; Xu et al., 2001) . The indication, from monochromosomal tumor cell hybrids, that there are dierent genetic loci which can shut down hTERT expression, suggests that perhaps repression of hTERT is due to diuse mechanisms that aect the chromatin structure in and around the hTERT gene, rather than to a few well de®ned target sites of sequence speci®c repressors or activators. In this context it may be relevant that the hTERT gene is close to the telomere of the short arm of chromosome 5. This raises the possibility that the gene is subject to telomeric repression which has recently been shown to exist in human cells (Baur et al., 2001 ). The precise position of the hTERT gene has not yet been determined (Bryce et al., 2000) . It will be interesting to test whether expression of other genes close to the telomere of chromosome 5p correlates with that of hTERT.
Note added to proof
Telomere loss itself can lead to chromosomal instability (Blasco et al., 1997) , and experiments with telomerasede®cient mice show that this correlates with a very strong increase in the incidence of carcinomas (Artandi et al., 2000) . What the contribution of telomere loss to genome instability in the evolution of human tumors is remains to be analysed. The answer to this question depends, in part, on what fraction of tumors is derived from telomerase positive stem cells.
